Table 2 Efficacy of Genetic testing regimen for minor stroke and acute TIA patients.

From: Cost-effectiveness of CYP2C19 genotyping to guide antiplatelet therapy for acute minor stroke and high-risk transient ischemic attack

Model input

 

Genetic testing

 

Non-genetic testing

References

Proportion of patients after 90 days

    

19,32

Minor or no disability (mRS 0–2)

 

0.9506

 

0.9376

 

Moderate disability (mRS 3–4)

 

0.0404

 

0.0527

 

Severe disability (mRS 5)

 

0.0054

 

0.0058

 

Death (mRS 6)

 

0.0036

 

0.0039

 

90-day event risks

CYP2C19 LoFA non-carriers*

CYP2C19 LoFA carriers† and ESRS ≥ 3

CYP2C19 LoFA carriers and ESRS < 3

 

19,21,32

Recurrent stroke

0.0717

0.0871

0.0727

0.082

 

Proportion of ICH

0.0377

0.0377

0.0377

0.0377

 

Major ECH

0.0108

0.0108

0.0108

0.0108

 

MI

0.0012

0.0012

0.0012

0.0012

 
  1. Minor stroke minor stroke, TIA transient ischemic attack, mRS modified Rankin Score, ICH intracerebral hemorrhage, ECH extracranial hemorrhage, MI myocardial infarction.
  2. *CYP2C19 LoFA non-carriers were defined as patients without LoFA of *2 and *3 (*1/*1, *1/*17, or *17/*17).
  3. †CYP2C19 LoFA carriers were defined as patients with at least one LoFA of *2 or *3 (*1/*2, *1/*3, *2/*2, *2/*3, *3/*3, *2/*17, or *3/*17).
Back to article page